MedTrace Logo

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT05997927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2024-07-29

No results posted yet for this study

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

Conditions

  • Moderate to Severe Atopic Dermatitis

Interventions

DRUG

VC005 tablets

VC005 groups repeat administration for 12 weeks

DRUG

VC005 Tablets Placebo

VC005 placebo groups repeat administration for 12 weeks

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • Qianjin Lu · Chinese Academy of Medical Sciences Hospital of Skin Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-20
Primary Completion
2024-07-09
Completion
2024-07-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05997927 on ClinicalTrials.gov